Pharmaceuticals

Drug Repositioning Service Market Future Outlook 2026: Key Drivers and Growth Potential

February 13, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the drug repositioning service market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Drug Repositioning Service Market from 2026 to 2030?

The drug repositioning service market has experienced robust growth in recent years. Its value is projected to expand from $34.2 billion in 2025 to $36.19 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. This market’s historical expansion can be attributed to several factors, including escalating pharmaceutical research and development costs, the abundance of extensive legacy drug data, an increasing incidence of failed clinical trials, a rising need for accelerated drug development cycles, and the prompt integration of computational drug discovery methods.

The drug repositioning service market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a size of $45.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.1%. Several factors will drive this growth during the forecast period, including a heightened need for economical drug development, the growing use of AI-powered discovery instruments, an increased emphasis on rare and orphan diseases, the broadening scope of data-informed clinical research, and improved regulatory approval for drugs that have been repurposed. Key trends expected during this period involve the increasing deployment of AI-based drug repurposing platforms, a greater emphasis on re-evaluating drugs that failed in clinical trials, the expanding incorporation of real-world data into drug discovery processes, the development of precision medicine-focused repositioning strategies, and stronger partnerships between pharmaceutical companies and contract research organizations (CROs).

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=29040&type=smp

What Drivers Are Affecting Demand In The Drug Repositioning Service Market?

The increasing spending on healthcare is anticipated to drive expansion in the drug repositioning service market in the future. These expenditures encompass all financial outlays for health services, covering aspects such as disease prevention, medical treatment, recovery efforts, and administrative functions. The primary reasons for this escalation in healthcare spending are the escalating costs of medical care, spurred by innovations in technology, and an expanding need for health services. Elevated healthcare spending supports drug repositioning services, as greater financial resources facilitate a higher volume of clinical trials and research initiatives, thereby speeding up the discovery of novel therapeutic applications for currently available medications. An example of this trend is observed in May 2024, when the Office for National Statistics, a UK-based Government department, reported that total healthcare expenditure saw a substantial increase of 5.6% in nominal terms between 2022 and 2023. Consequently, the uptick in healthcare spending is fueling the expansion of the drug repositioning service market.

Which Segments Are Gaining Traction In The Drug Repositioning Service Market?

The drug repositioning service market covered in this report is segmented –

1) By Type: Generic Drugs, Clinical Trial Failed Drugs

2) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Other Therapeutic Area

3) By End-User: Pharmaceutical Companies, Biotechnology Firms, Contract Research Organizations (CROs), Academic Research Institutions, Hospitals And Ambulatory Surgical Centers.

Subsegments:

1) By Generic Drugs: Small Molecule Drugs, Biologics, Biosimilars, Peptide-Based Drugs

2) By Clinical Trial Failed Drugs: Phase I Failed Drugs, Phase II Failed Drugs, Phase III Failed Drugs, Safety-Related Failed Drugs, Efficacy-Related Failed Drugs

Which Competitive Trends Are Impacting The Structure Of The Drug Repositioning Service Market?

Leading firms in the drug repositioning service market are increasingly adopting artificial intelligence (AI) for drug repositioning, particularly computational drug repositioning systems. These systems leverage AI-driven analysis of literature and biological data to systematically uncover novel therapeutic uses for existing drugs. A computational drug repositioning system is essentially a technology-powered platform that utilizes AI, machine learning, and data mining to meticulously examine existing drugs, compounds, and biological datasets. For instance, in November 2024, the Japanese companies UBE and FRONTEO initiated a collaborative co-creation project. This project establishes a framework for integrating the specialized knowledge of both UBE and FRONTEO to bolster drug repositioning efforts. It facilitates smooth collaboration between dry research (data analysis) and wet research (biological testing), thereby streamlining the transition from initial hypotheses to experimental validation. By employing FRONTEO’s AI-driven Drug Discovery AI Factory and KIBIT technology, the initiative systematically identifies previously unknown connections between diseases and molecules.

Who Are The Major Companies Operating In The Drug Repositioning Service Market?

Major companies operating in the drug repositioning service market are Recursion Pharmaceuticals Inc., Excelra, LifeArc, Cosmos Health Inc., Fios Genomics, Insilico Medicine Inc., Melior Discovery, Delta4, Acubiosys, VeriSIM Life, BioXcel Therapeutics Inc., Pharnext S.S., NuMedii, GVK Biosciences, Plex Research, Paradigm Biopharmaceuticals, BenevolentAI Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/drug-repositioning-service-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Drug Repositioning Service Market?

North America was the largest region in the drug repositioning service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repositioning service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Drug Repositioning Service Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=29040&type=smp

Browse Through More Reports Similar to the Global Drug Repositioning Service Market 2026, By The Business Research Company

Drug Discovery Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-discovery-services-global-market-report

Controlled Substance Market Report 2026

https://www.thebusinessresearchcompany.com/report/controlled-substance-global-market-report

Behavioral Rehabilitation Market Report 2026

https://www.thebusinessresearchcompany.com/report/behavioral-rehabilitation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795